DDInter1233 DDInter53
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Mitotane {u} (Compound) binds {v} (Gene) CYP11B1
CYP11B1 {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Mitotane {u} (Compound) binds {v} (Gene) CYP11A1
CYP11A1 {u} (Gene) is bound by {v} (Compound) Terbinafine
Terbinafine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Mitotane {u} (Compound) upregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) is upregulated by {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Mitotane {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is downregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Mitotane {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Cytochrome P450 3A4 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Mitotane {u} (Compound) downregulates {v} (Gene) PEG10
PEG10 {u} (Gene) is downregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Mitotane {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Cytochrome P450 3A4 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Oritavancin
Oritavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Mitotane {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Mitotane (Compound) binds CYP11B1 (Gene) and CYP11B1 (Gene) is bound by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Alpelisib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Mitotane (Compound) binds CYP11A1 (Gene) and CYP11A1 (Gene) is bound by Terbinafine (Compound) and Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Mitotane (Compound) upregulates ADGRE5 (Gene) and ADGRE5 (Gene) is upregulated by Isotretinoin (Compound) and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Mitotane (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is downregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Mitotane (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class) and Cytochrome P450 3A4 Inducers (Pharmacologic Class) includes Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Alpelisib
Mitotane (Compound) downregulates PEG10 (Gene) and PEG10 (Gene) is downregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Mitotane (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class) and Cytochrome P450 3A4 Inducers (Pharmacologic Class) includes Oritavancin (Compound) and Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Mitotane (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib